Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer

Conclusions: OPB-111077 can be given safely and achieves clinically active drug levels in humans. Single agent clinical activity was observed. Translational work is ongoing to determine factors driving clinical activityCitation Format: Gregory Cote, Kyriakos Papadopoulos, Amita Patnaik, Drew Rascoe, Lon Smith, Andrea Bullock, Keith Flaherty, Geoffrey Shapiro, Jordan Berlin, Manish Monga, Thomas Habermann, Thomas Witzig, Chester Lin, Lin-Feng Tsai, Agnes Elekes, Naoto Ohi, Kunihiko Tatsumi, Anthony Tolcher. A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118.

Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Cote, G., Papadopoulos, K., Patnaik, A., Rascoe, D., Smith, L., Bullock, A., Flaherty, K., Shapiro, G., Berlin, J., Monga, M., Habermann, T., Witzig, T., Lin, C., Tsai, L.-F., Elekes, A., Ohi, N., Tatsumi, K., Tolcher, A. Tags: New Molecular Targets: Poster Presentations - Proffered Abstracts Source Type: research